



Press Release

ABIONYX Pharma announces its financial agenda for the year 2022

Toulouse, FRANCE, Lakeland MI, UNITED-STATES, January 31, 2022, 5:45 pm CET **ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible)**, a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2022.

Events	Date*
Cash position and activity update for Q4 2021	February 24, 2022
2021 Annual Results	April 28, 2022
Cash position and activity update for Q1 2022	May 19, 2022
Cash position and activity update for Q2 2022	August 18, 2022
2022 Half Year Results	September 29, 2022
Cash position and activity update for Q3 2022	November 17, 2022

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.

Contacts:

NewCap

Investor relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap

Media relations
Nicolas Merigeau
abionyx@newcap.eu
+33 (0)1 44 71 94 98